Merck signs $2.1bn SciBrunch Oncology Deal
Multinational biopharmaceutical company Merck has entered into an exclusive global licensing agreement with Chinese biotechnology firm SciBrunch Therapeutics for the development and commercialisation of SPR2015. SPR2015 is an investigational, preclinical, oral molecular glue inhibitor specifically engineered to target a mutation which is one of the most prevalent genetic alterations across major malignancies, including pancreatic, colorectal, and non small cell lung…